oregovomab + niraparib

Oregovomab + niraparib is an investigational combination therapy for platinum-sensitive recurrent ovarian cancer. It combines **oregovomab**, a monoclonal antibody targeting the CA125 (MUC16) antigen on ovarian cancer cells—stimulating an anti-tumor immune response—with **niraparib**, an oral small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), designed to block DNA repair in cancer cells. The rationale for the combination is to synergize immune-mediated targeting of tumor cells (via oregovomab) with synthetic lethality from DNA repair inhibition (via niraparib), aiming to enhance disease control beyond what either agent achieves alone[1][2][3][4][6].